Table 2.
Univariate analysis of comorbidities as indicators for disease progression among Japanese and German patients at diagnosis. Patients showing one specified comorbidity alone or a combination were enrolled in the yes group. Data indicate an association between comorbidity and higher odds of developing a more severe illness with a 95% confidence interval (CI). Data are n (% of patients in each group). p values were calculated by X2 test or Fischer’s exact test.
| GERMANY | JAPAN | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Uncomplicated | Complicated | Critical | p-Value | Total | Uncomplicated | Complicated | Critical | p-Value | |
| Heart | ||||||||||
| Yes | 3355 | 2080.0 (62.0%) | 1011.0 (30.13%) | 264.0 (7.87%) | 0 | 13 | 5.0 (38.46%) | 8.0 (61.54%) | 0.0 (0.0%) | 0 |
| No | 2704 | 2081.0 (76.96%) | 502.0 (18.57%) | 121.0 (4.47%) | 161 | 142.0 (88.2%) | 14.0 (8.7%) | 5.0 (3.11%) | ||
| Hypertension | ||||||||||
| Yes | 2914 | 1800.0 (61.77%) | 879.0 (30.16%) | 235.0 (8.06%) | 0 | 50 | 32.0 (64.0%) | 18.0 (36.0%) | 0.0 (0.0%) | 0 |
| No | 3028 | 2301.0 (75.99%) | 602.0 (19.88%) | 125.0 (4.13%) | 124 | 115.0 (92.74%) | 4.0 (3.23%) | 5.0 (4.03%) | ||
| Diabetes | ||||||||||
| Yes | 1235 | 705.0 (57.09%) | 417.0 (33.77%) | 113.0 (9.15%) | 0 | 27 | 18.0 (66.67%) | 8.0 (29.63%) | 1.0 (3.7%) | 0.0127 |
| No | 4824 | 3456.0 (71.64%) | 1096.0 (22.72%) | 272.0 (5.64%) | 147 | 129.0 (87.76%) | 14.0 (9.52%) | 4.0 (2.72%) | ||
| Dementia | ||||||||||
| Yes | 503 | 295.0 (58.65%) | 178.0 (35.39%) | 30.0 (5.96%) | 0 | 10 | 4.0 (40.0%) | 5.0 (50.0%) | 1.0 (10.0%) | 0.0011 |
| No | 5369 | 3769.0 (70.2%) | 1273.0 (23.71%) | 327.0 (6.09%) | 164 | 143.0 (87.2%) | 17.0 (10.37%) | 4.0 (2.44%) | ||
| Kidney | ||||||||||
| Yes | 843 | 506.0 (60.02%) | 285.0 (33.81%) | 52.0 (6.17%) | 0 | 12 | 8.0 (66.67%) | 4.0 (33.33%) | 0.0 (0.0%) | 0.0944 |
| No | 5047 | 3567.0 (70.68%) | 1175.0 (23.28%) | 305.0 (6.04%) | 162 | 139.0 (85.8%) | 18.0 (11.11%) | 5.0 (3.09%) | ||
| Hemiplegia | ||||||||||
| Yes | 96 | 49.0 (51.04%) | 36.0 (37.5%) | 11.0 (11.46%) | 0 | 4 | 2.0 (50.0%) | 1.0 (25.0%) | 1.0 (25.0%) | 0.1142 |
| No | 5771 | 4012.0 (69.52%) | 1412.0 (24.47%) | 347.0 (6.01%) | 170 | 145.0 (85.29%) | 21.0 (12.35%) | 4.0 (2.35%) | ||
| Cerebrovascular | ||||||||||
| Yes | 505 | 302.0 (59.8%) | 169.0 (33.47%) | 34.0 (6.73%) | 0 | 4 | 2.0 (50.0%) | 2.0 (50.0%) | 0.0 (0.0%) | 0.1142 |
| No | 5554 | 3859.0 (69.48%) | 1344.0 (24.2%) | 351.0 (6.32%) | 170 | 145.0 (85.29%) | 20.0 (11.76%) | 5.0 (2.94%) | ||
| Vascular | ||||||||||
| Yes | 254 | 144.0 (56.69%) | 91.0 (35.83%) | 19.0 (7.48%) | 0 | 4 | 2.0 (50.0%) | 2.0 (50.0%) | 0.0 (0.0%) | 0.1142 |
| No | 5564 | 3893.0 (69.97%) | 1337.0 (24.03%) | 334.0 (6.0%) | 170 | 145.0 (85.29%) | 20.0 (11.76%) | 5.0 (2.94%) | ||
| Respiratory | ||||||||||
| Yes | 862 | 524.0 (60.79%) | 270.0 (31.32%) | 68.0 (7.89%) | 0 | 4 | 3.0 (75.0%) | 1.0 (25.0%) | 0.0 (0.0%) | 0.4938 |
| No | 5197 | 3637.0 (69.98%) | 1243.0 (23.92%) | 317.0 (6.1%) | 170 | 144.0 (84.71%) | 21.0 (12.35%) | 5.0 (2.94%) | ||
| Immunosuppressive | ||||||||||
| Yes | 393 | 268.0 (68.19%) | 105.0 (26.72%) | 20.0 (5.09%) | 0.7526 | 10 | 7.0 (70.0%) | 3.0 (30.0%) | 0.0 (0.0%) | 0.4387 |
| No | 5666 | 3893.0 (68.71%) | 1408.0 (24.85%) | 365.0 (6.44%) | 118 | 94.0 (79.66%) | 19.0 (16.1%) | 5.0 (4.24%) | ||
| Cancer | ||||||||||
| Yes | 766 | 509.0 (66.45%) | 223.0 (29.11%) | 34.0 (4.44%) | 0.1333 | 12 | 11.0 (91.67%) | 1.0 (8.33%) | 0.0 (0.0%) | 0.4583 |
| No | 5293 | 3652.0 (69.0%) | 1290.0 (24.37%) | 351.0 (6.63%) | 116 | 90.0 (77.59%) | 21.0 (18.1%) | 5.0 (4.31%) | ||
| Liver | ||||||||||
| Yes | 152 | 105.0 (69.08%) | 35.0 (23.03%) | 12.0 (7.89%) | 0.9598 | 34 | 24.0 (70.59%) | 9.0 (26.47%) | 1.0 (2.94%) | 0.2534 |
| No | 5907 | 4056.0 (68.66%) | 1478.0 (25.02%) | 373.0 (6.31%) | 94 | 77.0 (81.91%) | 13.0 (13.83%) | 4.0 (4.26%) | ||
| Gastro | ||||||||||
| Yes | 105 | 65.0 (61.9%) | 30.0 (28.57%) | 10.0 (9.52%) | 0 | 0 | 0.0 (nan%) | 0.0 (nan%) | 0.0 (nan%) | 1 |
| No | 5757 | 3993.0 (69.36%) | 1418.0 (24.63%) | 346.0 (6.01%) | 174 | 147.0 (84.48%) | 22.0 (12.64%) | 5.0 (2.87%) | ||